annual EBITDA:
-$447.31M-$244.61M(-120.67%)Summary
- As of today (June 25, 2025), CRSP annual EBITDA is -$447.31 million, with the most recent change of -$244.61 million (-120.67%) on December 31, 2024.
- During the last 3 years, CRSP annual EBITDA has fallen by -$838.79 million (-214.26%).
- CRSP annual EBITDA is now -214.26% below its all-time high of $391.48 million, reached on December 31, 2021.
Performance
CRSP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$143.69M-$83.94M(-140.50%)Summary
- As of today (June 25, 2025), CRSP quarterly EBITDA is -$143.69 million, with the most recent change of -$83.94 million (-140.50%) on March 31, 2025.
- Over the past year, CRSP quarterly EBITDA has dropped by -$7.93 million (-5.84%).
- CRSP quarterly EBITDA is now -118.75% below its all-time high of $766.27 million, reached on June 30, 2021.
Performance
CRSP quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$455.24M-$7.93M(-1.77%)Summary
- As of today (June 25, 2025), CRSP TTM EBITDA is -$455.24 million, with the most recent change of -$7.93 million (-1.77%) on March 31, 2025.
- Over the past year, CRSP TTM EBITDA has dropped by -$176.22 million (-63.16%).
- CRSP TTM EBITDA is now -199.14% below its all-time high of $459.18 million, reached on June 30, 2021.
Performance
CRSP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CRSP EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -120.7% | -5.8% | -63.2% |
| 3 y3 years | -214.3% | +15.4% | -236.6% |
| 5 y5 years | -969.1% | -101.0% | -1750.6% |
CRSP EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -214.3% | +31.1% | -292.9% | +19.0% | -236.6% | +31.3% |
| 5 y | 5-year | -214.3% | +31.1% | -118.8% | +19.0% | -199.1% | +31.3% |
| alltime | all time | -214.3% | +31.1% | -118.8% | +19.0% | -199.1% | +31.3% |
CRSP EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$143.69M(+140.5%) | -$455.24M(+1.8%) |
| Dec 2024 | -$447.31M(+120.7%) | -$59.75M(-43.3%) | -$447.31M(+42.9%) |
| Sep 2024 | - | -$105.39M(-28.0%) | -$313.08M(-6.6%) |
| Jun 2024 | - | -$146.41M(+7.9%) | -$335.17M(+20.1%) |
| Mar 2024 | - | -$135.75M(-282.3%) | -$279.02M(+37.7%) |
| Dec 2023 | -$202.70M(-68.8%) | $74.48M(-158.4%) | -$202.70M(-49.7%) |
| Sep 2023 | - | -$127.49M(+41.2%) | -$402.88M(-11.0%) |
| Jun 2023 | - | -$90.26M(+51.9%) | -$452.76M(-15.9%) |
| Mar 2023 | - | -$59.44M(-52.7%) | -$538.49M(-17.0%) |
| Dec 2022 | -$648.99M(-265.8%) | -$125.69M(-29.1%) | -$648.99M(-2.1%) |
| Sep 2022 | - | -$177.37M(+0.8%) | -$662.73M(+8.8%) |
| Jun 2022 | - | -$175.99M(+3.6%) | -$608.89M(-282.6%) |
| Mar 2022 | - | -$169.93M(+21.9%) | $333.38M(-14.8%) |
| Dec 2021 | $391.48M(-213.4%) | -$139.44M(+12.9%) | $391.48M(-8.0%) |
| Sep 2021 | - | -$123.53M(-116.1%) | $425.72M(-7.3%) |
| Jun 2021 | - | $766.27M(-785.2%) | $459.18M(-219.1%) |
| Mar 2021 | - | -$111.83M(+6.3%) | -$385.58M(+11.7%) |
| Dec 2020 | -$345.25M | -$105.19M(+16.8%) | -$345.25M(+51.7%) |
| Sep 2020 | - | -$90.06M(+14.7%) | -$227.64M(-8034.5%) |
| Jun 2020 | - | -$78.50M(+9.8%) | $2.87M(-89.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$71.50M(-675.9%) | $27.58M(-46.4%) |
| Dec 2019 | $51.47M(-133.1%) | $12.41M(-91.2%) | $51.47M(-1083.5%) |
| Sep 2019 | - | $140.45M(-361.1%) | -$5.23M(-97.3%) |
| Jun 2019 | - | -$53.78M(+13.0%) | -$194.23M(+9.8%) |
| Mar 2019 | - | -$47.61M(+7.5%) | -$176.86M(+13.8%) |
| Dec 2018 | -$155.42M(+152.2%) | -$44.28M(-8.8%) | -$155.42M(+42.1%) |
| Sep 2018 | - | -$48.55M(+33.3%) | -$109.36M(+30.8%) |
| Jun 2018 | - | -$36.42M(+39.2%) | -$83.59M(+23.3%) |
| Mar 2018 | - | -$26.17M(-1571.9%) | -$67.77M(+10.0%) |
| Dec 2017 | -$61.62M(+348.4%) | $1.78M(-107.8%) | -$61.62M(+35.5%) |
| Sep 2017 | - | -$22.78M(+10.6%) | -$45.49M(+22.4%) |
| Jun 2017 | - | -$20.60M(+2.9%) | -$37.16M(+10.7%) |
| Mar 2017 | - | -$20.02M(-211.8%) | -$33.56M(+144.2%) |
| Dec 2016 | -$13.74M(-46.3%) | $17.91M(-223.9%) | -$13.74M(-68.6%) |
| Sep 2016 | - | -$14.45M(-15.0%) | -$43.71M(+23.4%) |
| Jun 2016 | - | -$16.99M(+7991.9%) | -$35.41M(+92.2%) |
| Mar 2016 | - | -$210.00K(-98.3%) | -$18.42M(+1.2%) |
| Dec 2015 | -$25.59M(+274.9%) | -$12.06M(+96.0%) | -$18.21M(+196.0%) |
| Sep 2015 | - | -$6.15M | -$6.15M |
| Dec 2014 | -$6.83M | - | - |
FAQ
- What is CRISPR Therapeutics AG annual EBITDA?
- What is the all time high annual EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
- What is CRISPR Therapeutics AG quarterly EBITDA?
- What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
- What is CRISPR Therapeutics AG TTM EBITDA?
- What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
What is CRISPR Therapeutics AG annual EBITDA?
The current annual EBITDA of CRSP is -$447.31M
What is the all time high annual EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual EBITDA is $391.48M
What is CRISPR Therapeutics AG annual EBITDA year-on-year change?
Over the past year, CRSP annual EBITDA has changed by -$244.61M (-120.67%)
What is CRISPR Therapeutics AG quarterly EBITDA?
The current quarterly EBITDA of CRSP is -$143.69M
What is the all time high quarterly EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly EBITDA is $766.27M
What is CRISPR Therapeutics AG quarterly EBITDA year-on-year change?
Over the past year, CRSP quarterly EBITDA has changed by -$7.93M (-5.84%)
What is CRISPR Therapeutics AG TTM EBITDA?
The current TTM EBITDA of CRSP is -$455.24M
What is the all time high TTM EBITDA for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high TTM EBITDA is $459.18M
What is CRISPR Therapeutics AG TTM EBITDA year-on-year change?
Over the past year, CRSP TTM EBITDA has changed by -$176.22M (-63.16%)